Sealife360 International Ventures Corporation is proud to announce the launch of Hemaway, a new drug designed to treat hemorrhoids — a common but often unspoken condition affecting people of all ages, statuses, and genders.
Hemorrhoids, which occur in the anal region, can be internal or external, leading to discomfort, pain, and complications if left untreated.
Dr. Antonio Ligsay, a renowned pediatrician, epidemiologist, and medical researcher, explains that hemorrhoids are often caused by factors such as straining during bowel movements, obesity, anal intercourse, pregnancy, and prolonged sitting. “Anything that increases pressure in the anal region can lead to hemorrhoids,” Dr. Ligsay states.
Untreated hemorrhoids can result in complications such as strangulation, anemia, and blood clots. However, Dr. Ligsay assures that 90% of hemorrhoid cases can be effectively treated with medication, with only a small percentage requiring surgical intervention. “Only 10% will be treated through surgery. Regardless of treatment method, medical treatment is essential,” he emphasizes.
Sealife360’s new product, Hemaway (Diosmin+Hesperidin), is a plant-based drug that is proven to be safe and effective under physician supervision. Research indicates that diosmin and hesperidin can significantly reduce hemorrhoid symptoms and prevent recurrence.
“Hemorrhoids is a disease that can be easily treated using the right medication paired with dietary and lifestyle changes,” says Dr. Ligsay. He also advises consulting a doctor if blood is present in bowel movements or if hemorrhoids do not improve after a week of treatment and home care.
Hemaway will be available exclusively in Mercury drugstores nationwide starting August this year.
